# Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma

> **NCT05061251** · EARLY_PHASE1 · WITHDRAWN · sponsor: **University of Texas Southwestern Medical Center**

## Conditions studied

- Glioma
- IDH Mutation

## Interventions

- **DRUG:** BAY 2402234

## Key facts

- **NCT ID:** NCT05061251
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Drug availability
- **Last updated:** 2022-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05061251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05061251, "Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05061251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*